Recent developments in the clinical activity of topoisomerase-1 inhibitors (Q61773324)

Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

The impact of tumor physiology on camptothecin-based drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Reduced albumin binding promotes the stability and activity of topotecan in human blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Gender-dependent pharmacokinetics of topotecan in adult patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Effect of carboxylesterase inhibition on the anti-tumour effects of irinotecan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Human UDP-glucuronosyltransferases: metabolism, expression, and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Repair of and checkpoint response to topoisomerase I-mediated DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Effects of camptothecin on double-strand break repair by non-homologous end-joining in DNA mismatch repair-deficient human colorectal cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Transcription-dependent degradation of topoisomerase I-DNA covalent complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Subnuclear distribution of DNA topoisomerase I and Bax protein in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and gamma rays or treatment with topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

SUMO, ubiquitin's mysterious cousin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Combined Therapy with Topotecan and Gemcitabine in Patients with Inoperable or Metastatic Non-small Cell Lung Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Combined topoisomerase I inhibition for the treatment of metastatic colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A pilot study of topotecan in the treatment of serous carcinoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase II study of topotecan in patients with relapsed small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II Trial of Irinotecan (CPT-11) in Relapsed or Refractory Non-Hodgki n's Lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

9-Aminocamptothecin and beyond. Preclinical and clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human hematopoietic and other cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II trial of oral rubitecan in previously treated pancreatic cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010

Role of red blood cells in pharmacokinetics of chemotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCT.2006.05.010